Frederick Hiller Ii Institution Verified

Sourced from institutional research profiles (UAMS TRI or ARA).

UAMS Contingent Worker

University of Arkansas for Medical Sciences

grad_student

Internal Med, College of Medicine

Research Areas

Health Sciences Research and Education Internal Medicine

Links

Research Group UAMS TRI Profile

Edit your profile

OverviewAI-generated summary

Frederick Hiller II's work at the University of Arkansas for Medical Sciences focuses on research within Internal Medicine. His contributions are situated within the College of Medicine, where he holds a contingent worker position. His research efforts are part of the broader medical and scientific endeavors undertaken at the institution, contributing to the field of internal medicine through his work.

Grants & Funding

A 52-week, Double-Blind, Randomized, Placebo Controlled Parallel Group Study to Evaluate the Effect of Roflumilast 500 µg on Exacerbation Rate in Subj Forest Research Institute Principal Investigator
Protocol 3000-0409: Phase III, Randomized, Open-Label, Study of Aquavan Injection vs Midazolam HCL for Sedation in Patients Undergoing Flexible Bronch PPD Development, LP Principal Investigator
a comparative study of LAS 34273 versus placebo in the treatment of stable, moderate to severe COPD, also known as ACCLAIM II Almirall Prodesfarma, S.A. Principal Investigator
Protocol 3000-0409: Phase III, Randomized, Open-Label, Study of Aquavan Injection vs Midazolam HCL for Sedation in Patients Undergoing Flexible Bronch PPD Development, LP Principal Investigator
A randomized, multicenter, placebo-controlled parallel group study of four months duration per subject to evaluate the safety and efficacy of treatmen NOVARTIS Pharmaceuticals Corporation Principal Investigator
Effect of roflumilast on exacerbation rate in patients with COPD. A 52 week, double-blind study with 500 mcg roflumilast once daily versus placebo. Altana Pharma Principal Investigator
Protocol No. NA17098, “A Multi-Center, Randomized, Double-Blind, Placebo, Controlled Phase 2a Dose-Response Study of the Safety and Tolerability of Tw Hoffmann-La Roche, Inc. Principal Investigator
A randomized, multicenter, placebo-controlled parallel group study of four months duration per subject to evaluate the safety and efficacy of treatmen NOVARTIS Pharmaceuticals Corporation Principal Investigator